Skip to main content
. 2010 May;221(1):49–56. doi: 10.1002/path.2696

Table 2.

Clinical characteristics of the validation study patients

Validation set (n = 82
PFS (months)
 Median 13.3
OS (months)
 Median 34
Age (years)
 Median 61.3
 Range 40.4–79.3
Stage (n)
 III 73
 IV 9
Grade (n)
 2 18
 3 63
 Unknown 1
Chemotherapy (n)
 Adjuvant 71
 Neo-adjuvant 11
Residual disease (n)
 No residual disease 16
 ≤1 cm 26
 > 1 cm and ≤2 cm 5
 > 2 cm 25
 Unknown 10
TP53 (n)
 Wild type 6
 Mutant 76

OS = overall survival; PFS = progression-free survival.